Document Detail

Renin inhibition.
MedLine Citation:
PMID:  16914963     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: Initial attempts to inhibit renin in humans have faced numerous difficulties. Molecular modeling and X-ray crystallography of the active site of renin have led to the development of new orally active renin inhibitors, such as aliskiren. Recent preclinical and clinical data suggest that this drug may be of value for treating patients with cardiovascular and renal disorders. RECENT FINDINGS: The once-daily administration of aliskiren to hypertensive patients lowers blood pressure as strongly as, or more strongly than, standard doses of established angiotensin II type 1 receptor blockers. It further decreases blood pressure in combination with hydrochlorothiazide. The biochemical consequences of renin inhibition differ from those of angiotensin I-converting enzyme inhibition and angiotensin II antagonism, particularly in terms of angiotensin profiles and interactions with the bradykinin-nitric oxide-cGMP pathway and possibly the (pro)renin receptor. SUMMARY: Blockade of the renin-angiotensin system with angiotensin I-converting enzyme inhibitors, angiotensin II type 1 receptor blockers or a combination of these drugs has become one of the most successful therapeutic approaches in medicine. It remains unclear, however, as to how to optimize the renin-angiotensin system blockade to maximize cardiovascular and renal benefits. In this context, renin inhibition to render the renin-angiotensin system fully quiescent is a new possibility requiring further study.
Michel Azizi
Related Documents :
3523313 - Effects of salmon calcitonin on plasma renin activity and systolic blood pressure in th...
2942423 - Hemodynamic effects of atrial natriuretic hormone.
16290353 - Direct measurement of the laplace pressure in a very thin liquid film.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in nephrology and hypertension     Volume:  15     ISSN:  1062-4821     ISO Abbreviation:  Curr. Opin. Nephrol. Hypertens.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-17     Completed Date:  2007-02-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9303753     Medline TA:  Curr Opin Nephrol Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  505-10     Citation Subset:  IM    
Université Paris Descartes, Faculté de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fumarates / pharmacology
Protein Precursors / metabolism
Receptors, Cell Surface / metabolism
Renin / antagonists & inhibitors*,  metabolism
Renin-Angiotensin System / drug effects*
Reg. No./Substance:
0/Amides; 0/Fumarates; 0/Protein Precursors; 0/Receptors, Cell Surface; 0/aliskiren; 0/prorenin receptor; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antihypertensive therapy and cerebrovascular protection.
Next Document:  Molecular physiology of renal ClC chloride channels/transporters.